Key Details
Price
$1.19Annual ROE
-84.82%Beta
0.79Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products
FEMY gains after FDA clearance for FemChec, a fallopian tube diagnostic tool designed for safe, in-office use, enhancing non-surgical birth control procedures.
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society's (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.
FEMY's eco-friendly FemVue MINI receives CE Mark and Health Canada approval, advancing sustainable fallopian tube assessment technology in Europe and Canada.
FAQ
- What is the ticker symbol for Femasys?
- Does Femasys pay dividends?
- What sector is Femasys in?
- What industry is Femasys in?
- What country is Femasys based in?
- When did Femasys go public?
- Is Femasys in the S&P 500?
- Is Femasys in the NASDAQ 100?
- Is Femasys in the Dow Jones?
- When was Femasys's last earnings report?
- When does Femasys report earnings?
- Should I buy Femasys stock now?